138 related articles for article (PubMed ID: 22898254)
1. Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility.
Ohashi T; Oguro Y; Tanaka T; Shiokawa Z; Tanaka Y; Shibata S; Sato Y; Yamakawa H; Hattori H; Yamamoto Y; Kondo S; Miyamoto M; Nishihara M; Ishimura Y; Tojo H; Baba A; Sasaki S
Bioorg Med Chem; 2012 Sep; 20(18):5507-17. PubMed ID: 22898254
[TBL] [Abstract][Full Text] [Related]
2. Discovery of pyrrolo[3,2-c]quinoline-4-one derivatives as novel hedgehog signaling inhibitors.
Ohashi T; Oguro Y; Tanaka T; Shiokawa Z; Shibata S; Sato Y; Yamakawa H; Hattori H; Yamamoto Y; Kondo S; Miyamoto M; Tojo H; Baba A; Sasaki S
Bioorg Med Chem; 2012 Sep; 20(18):5496-506. PubMed ID: 22910224
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice.
Kogame A; Tagawa Y; Shibata S; Tojo H; Miyamoto M; Tohyama K; Kondo T; Prakash S; Shyu WC; Asahi S
Drug Metab Dispos; 2013 Apr; 41(4):727-34. PubMed ID: 23298863
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of hedgehog signaling inhibitor with novel core system.
Ohashi T; Tanaka Y; Shiokawa Z; Banno H; Tanaka T; Shibata S; Satoh Y; Yamakawa H; Yamamoto Y; Hattori H; Kondo S; Miyamoto M; Tojo H; Baba A; Sasaki S
Bioorg Med Chem; 2015 Aug; 23(15):4777-4791. PubMed ID: 26094943
[TBL] [Abstract][Full Text] [Related]
5. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.
Ishii T; Shimizu Y; Nakashima K; Kondo S; Ogawa K; Sasaki S; Matsui H
Eur J Pharmacol; 2014 Jan; 723():305-13. PubMed ID: 24291104
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE
Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.
Goldman J; Eckhardt SG; Borad MJ; Curtis KK; Hidalgo M; Calvo E; Ryan DP; Wirth LJ; Parikh A; Partyka J; Faessel H; Gangolli E; Stewart S; Rosen LS; Bowles DW
Clin Cancer Res; 2015 Mar; 21(5):1002-9. PubMed ID: 25501576
[TBL] [Abstract][Full Text] [Related]
8. A small-molecule antagonist of the hedgehog signaling pathway.
Lee J; Wu X; Pasca di Magliano M; Peters EC; Wang Y; Hong J; Hebrok M; Ding S; Cho CY; Schultz PG
Chembiochem; 2007 Nov; 8(16):1916-9. PubMed ID: 17886323
[No Abstract] [Full Text] [Related]
9. GDC-0449-a potent inhibitor of the hedgehog pathway.
Robarge KD; Brunton SA; Castanedo GM; Cui Y; Dina MS; Goldsmith R; Gould SE; Guichert O; Gunzner JL; Halladay J; Jia W; Khojasteh C; Koehler MF; Kotkow K; La H; Lalonde RL; Lau K; Lee L; Marshall D; Marsters JC; Murray LJ; Qian C; Rubin LL; Salphati L; Stanley MS; Stibbard JH; Sutherlin DP; Ubhayaker S; Wang S; Wong S; Xie M
Bioorg Med Chem Lett; 2009 Oct; 19(19):5576-81. PubMed ID: 19716296
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of optimized phthalazine derivatives as hedgehog signaling pathway inhibitors.
Lu X; Peng Y; Wang C; Yang J; Bao X; Dong Q; Zhao W; Tan W; Dong X
Eur J Med Chem; 2017 Sep; 138():384-395. PubMed ID: 28688278
[TBL] [Abstract][Full Text] [Related]
11. Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier.
Rohner A; Spilker ME; Lam JL; Pascual B; Bartkowski D; Li QJ; Yang AH; Stevens G; Xu M; Wells PA; Planken S; Nair S; Sun S
Mol Cancer Ther; 2012 Jan; 11(1):57-65. PubMed ID: 22084163
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926).
Tremblay MR; Lescarbeau A; Grogan MJ; Tan E; Lin G; Austad BC; Yu LC; Behnke ML; Nair SJ; Hagel M; White K; Conley J; Manna JD; Alvarez-Diez TM; Hoyt J; Woodward CN; Sydor JR; Pink M; MacDougall J; Campbell MJ; Cushing J; Ferguson J; Curtis MS; McGovern K; Read MA; Palombella VJ; Adams J; Castro AC
J Med Chem; 2009 Jul; 52(14):4400-18. PubMed ID: 19522463
[TBL] [Abstract][Full Text] [Related]
13. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
Xin M; Zhang L; Jin Q; Tang F; Wen J; Gu L; Cheng L; Zhao Y
Eur J Med Chem; 2016 Mar; 110():115-25. PubMed ID: 26820554
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X
ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of novel dimethylpyridazine derivatives as hedgehog signaling pathway inhibitors.
Wang C; Zhu M; Lu X; Wang H; Zhao W; Zhang X; Dong X
Bioorg Med Chem; 2018 Jul; 26(12):3308-3320. PubMed ID: 29739714
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription.
Liu G; Huang W; Wang J; Liu X; Yang J; Zhang Y; Geng Y; Tan W; Zhang A
J Med Chem; 2017 Oct; 60(19):8218-8245. PubMed ID: 28873303
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and evaluation of hybrid vitamin D3 side chain analogues as hedgehog pathway inhibitors.
Banerjee U; DeBerardinis AM; Hadden MK
Bioorg Med Chem; 2015 Feb; 23(3):548-55. PubMed ID: 25549899
[TBL] [Abstract][Full Text] [Related]
19. Mitogen-activated kinase kinase kinase 1 inhibits hedgehog signaling and medulloblastoma growth through GLI1 phosphorylation.
Antonucci L; Di Magno L; D'Amico D; Manni S; Serrao SM; Di Pastena F; Bordone R; Yurtsever ZN; Caimano M; Petroni M; Giorgi A; Schininà ME; Yates Iii JR; Di Marcotullio L; De Smaele E; Checquolo S; Capalbo C; Agostinelli E; Maroder M; Coni S; Canettieri G
Int J Oncol; 2019 Feb; 54(2):505-514. PubMed ID: 30483764
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitors.
Xin M; Zhang L; Tang F; Tu C; Wen J; Zhao X; Liu Z; Cheng L; Shen H
Bioorg Med Chem; 2014 Feb; 22(4):1429-40. PubMed ID: 24486203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
